Recommended Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Antibodies | Purification of Regulatory Rheumatoid Factors with PD-1 Binding Activity for Autoimmune Therapy
2026-10-28
【Frontier Express】Antibodies | Longitudinal Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis Over 208 Weeks
2026-10-28
【Frontier Express】Nature Communications | The CHORUS Study of Canakinumab Combined with Chemoradiation and Durvalumab Consolidation in Unresectable Stage III Non-Small Cell Lung Cancer
2026-10-28
【Frontier Express】Nature Communications | Spatiotemporal Programmed Dual-Site Oral Nanovaccine for Colorectal Cancer: From Intestinal Priming to Local Tumor Boosting
2026-10-28
【Frontier Express】Nature Communications | CD200+ Fibroblasts Regulate the Immunoregulatory Function of Granulocytic Myeloid-Derived Suppressor Cells in Inflammatory Arthritis via PD-L1
2026-10-27
【Frontier Express】Nature Communications | KRAS Mutation-Specific Lysosome-Targeting Protein Degradation Based on a Lipoprotein-Mimetic Nanoplatform
2026-10-27
【Frontier Express】Nature Communications | Phase 3 Clinical Trial Results of Disitamab Vedotin versus Lapatinib plus Capecitabine for HER2-Positive Breast Cancer with Liver Metastases
2026-10-26






